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Carbon nanotubes (CNTs) were discovered in 1991 and shown to have certain unique physicochemical 
properties, attracting considerable interest in their application in various fields including drug delivery. 
The unique properties of CNTs such as ease of cellular uptake, high drug loading, thermal ablation, among 
others, render them useful for cancer therapy. Cancer is one of the most challenging diseases of modern 
times because its therapy involves distinguishing normal healthy cells from affected cells. Here, CNTs 
play a major role because phenomena such as EPR, allow CNTs to distinguish normal cells from affected 
ones, the Holy Grail in cancer therapy. Considerable work has been done on CNTs as drug delivery 
systems over the last two decades. However, concerns over certain issues such as biocompatibility and 
toxicity have been raised and warrant extensive research in this field.
Uniterms: Carbon nanotubes/properties. Carbon nanotubes/use/drugs delivery. Single-Walled Carbon 
Nanotube. Multiwalled Carbon Nanotube. Anticancer drugs/delivery. Cancer/therapy. Drugs/delivery.
Os nanotubos de carbono foram descobertos em 1991 e suas propriedades físico-químicas únicas 
demonstradas, despertando interesse em sua aplicação em vários campos, incluindo a entrega liberação 
de fármacos. As propriedades únicas dos nanotubos de carbono, tais como a facilidade de captação pela 
célula, carga alta de fármaco, ablação térmica, entre outras, tornaram-nos úteis para terapia de câncer, 
uma das doenças mais difíceis dos tempos modernos, pois sua terapia envolve a distinção entre as 
células normais saudáveis e as afetadas pela doença. Os nanotubos de carbono têm um papel importante 
nessa área porque fenômenos como EPR permitem que estes possam distinguir as células normais das 
afetadas, que é o Santo Graal na terapia do câncer. Trabalho considerável tem sido feito ao longo das 
duas últimas década com nanotubos de carbono, como sistemas de liberação de fármacos. No entanto, 
preocupações sobre algumas questões, como biocompatibilidade e toxicidade, surgiram ao longo do 
tempo, demandando extensas pesquisa nesse campo. 
Unitermos: Nanotubos de carbono/propriedades. Nanotubos de carbono/uso/liberação de fármacos. 
Nanotubo de carbono de parede única. Nanotubo de parede múltipla. Fármacos anticancer/liberação. 
Cancer/tratamento. Fármacos/liberação.
INTRODUCTION
Cancer ranks amongst the top three killers in modern 
society, next to heart and cerebrovascular diseases. In 
2009, approximately eight million people died from cancer 
worldwide according to the WHO. The chemotherapeutic 
agents used for the treatment of a range of cancers are 
always associated with severe, sometimes fatal, toxicity 
due to a lack of target specificity (Alderton et al.,1992). 
Several attempts have been made to reduce this serious 
side effect, for example by liposomal encapsulation of 
doxorubicin (Chon et al.,1995). Additionally, active 
drug targeting strategies are being developed to further 
enhance selectivity. Ever since their discovery in 1991 
by Iijima (Iijima, 1991), there has been intense interest 
in allotropes of carbon due to their unique physical and 
chemical properties, emerging as promising candidates 
for a multimodal drug delivery systems. They not only 
allow for the attachment of multiple copies of drug 
molecules, but can also be equipped with targeting 
agents and stealth molecules to evade clearance by the 
immune system. Furthermore, they hold several potential 
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advantages over other nano-sized delivery systems, such 
as an exceptionally high drug loading capacity due to their 
high surface area and the possibility for incorporating 
additional therapeutic and diagnostic moieties, either on 
the surface or their inner cavity. In addition, they interact 
with cellular membranes in a unique way: some types 
of carbon nanotubes (CNTs) have been reported to enter 
mammalian cells by an endocytosis-independent, “needle-
like” penetration mechanism, which allows for direct 
cytoplasmic delivery of therapeutic payloads (Kostarelos 
et al., 2007; Mu et al., 2009). A number of studies have 
already reported successful delivery of anti-cancer drugs 
to human cancer cells or tumor xenografts by means of 
carbon nanotubes (Heister et al., 2009; Liu et al., 2007; 
Ali-Boucetta et al., 2008; Zhang et al., 2009; Liu et al., 
2009; Li et al., 2010).
PROPERTIES OF CARBON NANOTUBES
A number of properties result from the regular 
formation of carbon atoms in graphene cylinders. 
Carbon nanotubes are a huge cylindrical large molecule 
consisting of a hexagonal arrangement of sp2 hybridized 
carbon atoms (C-C distance is about 1.4 Ǻ). The 
wall of CNTs consists of single or multiple layers of 
graphene sheets, of which those formed by rolling up of 
single sheet are called single-walled carbon nanotubes 
(SWCNTs) and those formed by rolling up of more than 
one sheet are called multi-walled CNTs (MWCNTs). 
Both SWCNTs and MWCNTs are capped at both ends 
of the tubes in a hemispherical arrangement of carbon 
networks called fullerenes warped up by the graphene 
sheet (Figure 1). The interlayer separation of the 
graphene layers of MWCNTs measures approximately 
0.34 nm on average, each forming an individual tube, 
with all the tubes having a larger outer diameter (2.5 
to 100 nm) than SWCNTs (0.6 to 2.4 nm). SWCNTs 
have a better defined wall, whereas MWCNTs are more 
likely to have structural defects, resulting in a less stable 
nanostructure. In the medical field, three main attributes 
of CNTs have been exploited:
·	 Their small size.
·	 Their high surface area to volume ratio.
·	 Their ability to contain chemicals.
Carbon nanotubes can be produced small enough to 
pass through holes in tumours or to transport DNA (Singh 
et al.,2005) The large surface to volume ratio provides a 
good platform for efficient transportation of chemicals 
and for the reactions needed for ultra-sensitive glucose 
detection (Muguruma et al., 2007).
CARBON NANOTUBES AND THEIR IMPOR-
TANCE IN ANTICANCER DRUG DELIVERY
Carbon nanotubes (CNTs) are allotropes of carbon 
with a cylindrical nanostructure. The discovery and 
subsequent widespread characterization of carbon 
nanotubes (CNTs) have opened up a class of materials 
with unexpected electrical, mechanical, and thermal 
properties (Alderton et al., 1992). The structure of CNTs 
can be imagined as the cylindrical roll-up of one or more 
graphene sheets containing only sp2 hybridized carbon 
atoms in a honeycomb arrangement (Tasis et al., 2006). 
Whether in the form of single-walled carbon nanotubes 
(SWCNTs) or multi-walled carbon nanotubes (MWCNTs), 
CNTs present several remarkable properties such as high 
aspect-ratio, ultra-light weight, tremendous strength, high 
thermal conductivity and significant electronic properties 
ranging from metallic to semiconducting (Ezzati et 
al., 2011; Lüer et al., 2009). CNTs may have different 
lengths ranging from several hundred nanometers to 
several millimeters, but their diameters depend on their 
class: SWCNTs are 0.4-3 nm in diameter and MWCNTs 
are 2-500 nm in diameter, depending on the method of 
synthesis (Kim et al.,2007). MWCNTs also consist of 
several cylinders of graphitic shells with a spacing layer of 
0.3–0.4 nm (Dolatabadi et al., 2011). CNTs are currently 
one of the most popular nanomaterials used in a number 
of applications including electronics, energy storage, 
solar cells, molecular separation, sensing, biosensing, 
and drug delivery (Dolatabadi et al., 2011; Alpatova et 
FIGURE 1 - The structure of SWCNTs with the two ends closed 
(Taylor et al.,2011).
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al., 2010). CNTs can be used as drug-delivery vehicles 
or ‘nanocarriers’ in cancer therapy and other areas of 
medicine without causing toxicity to healthy tissue while 
allowing prolonged release of the drug (Tasis et al.,2006).
In recent years, a wide range of different nanoscale 
drug delivery vectors have been evaluated (Pan et al., 
2004; Chithrani et al., 2006; Endo et al., 2008). Notably, 
single-walled carbon nanotubes (SWCNTs) have attracted 
considerable interest in this regard, as they offer potential 
advantages over the more widely studied metal nanoparticle 
systems. These advantages include their ability to carry 
a high cargo loading, intrinsic stability, and structural 
flexibility, which can prolong circulation time and hence 
the bioavailability of the drug molecules carried (Liu et 
al., 2008; Singh et al., 2006; Worle-Knirsch et al., 2006; 
Wang et al., 2004). Moreover, SWCNTs have been shown 
to enter mammalian cells (Cai et al., 2007; Chin et al., 
2007; Kam et al., 2004; Kostarelos et al., 2007) and due to 
their promising properties, SWCNT-based materials have 
already been investigated as potential delivery vehicles for 
intracellular transport of nucleic acids (Cai et al., 2007; Liu 
et al., 2007; Pantarotto et al., 2004), proteins (Kam et al., 
2004; Kam et al., 2005) and drug molecules (Prato et al., 
2008; Liu et al., 2007; Chen et al., 2008; Liu, Sun et al., 
2007). SWCNTs have been functionalized with antibodies 
and low-molecular-weight targeting agents, providing high 
efficiency for nanotube internalization into cells (Chen et 
al., 2008; Liu et al., 2007; Bottini et al., 2006; Cato et al., 
2008, Singh et al., 2005; Kang et al., 2008; Shao et al., 
2007; Welsher et al., 2008; Zeineldin et al., 2009).These 
systems also have higher loading capacity and allow for 
the incorporation of targeting agents and stealth molecules 
may also be added to evade the immune system.(Mu et 
al., 2009; Heister et al.,2009) Such systems have been 
loaded with drug molecules such as doxorubicin (DOX) 
via p-p stacking interactions, methotrexate, Paclitaxel and 
quercetin.(Modi et al., 2011; Dolatabadi et al., 2011; Wang 
et al., 2009; Yuan et al., 2006; Abarrategi et al., 2008; Fu 
et al., 2007). Nevertheless, the first generation SWCNTs 
proved to be unsuitable as drug delivery vectors as they 
tended to form bundles that disperse poorly in aqueous 
solutions and were therefore unsuitable for pharmacological 
use. To overcome this drawback, synthetic polymers such 
as poly(phenylacetylene) (Zeineldin et al., 2009, Yuan et 
al., 2006) and natural polymers such as polysaccharides 
(Kam et al., 2005; Yuan et al., 2006; Abarrategi et al., 2008; 
Fu et al., 2007; Hasegawa et al., 2004; Long et al., 2008; 
Numata et al., 2004; Zhang et al., 2008) have been used 
to encase SWCNTs via non-covalent interactions, thereby 
improving their compatibility with water and physiological 
environments.
ADVANTAGES OF CARBON NANOTUBES 
OVER CONVENTIONAL CANCER THERAPY
Conventional treatment such as surgery is hindered 
by accessibility to tumorous cells and the risk of operating 
near or on vital organs. Also, selective treatment in 
chemotherapy and radiation is limited. On the whole, 
present treatment methods are not very effective at 
stopping the spread or recurrence of cancer. Nanomedicine 
provides a means of targeted delivery of drugs. Since the 
cancerous cells are on the nanoscale, there is a potential 
for highly efficient drug delivery (Misra et al., 2010). This 
has two major benefits. First, the total quantity of drug 
required is less, a concern primarily associated with the 
more costly drugs. Additionally, no solvent is required for 
delivery of the drug, which means that undesired health 
effects from the solvent can be prevented. Second, a lower 
concentration of the toxin is delivered to other parts of 
the body, without the risk of the protective nanocarrier 
degrading. Thus, fewer health side effects are suffered by 
the patient undergoing treatment. A further advantage of 
nanocarriers is that a range of drugs can be attached for 
a variety of purposes including; therapeutic, diagnostic, 
targeting and barrier avoidance, effectively allowing a 
toolkit to enable treatment specific to each patient’s cancer.
METHODS FOR OPENING, FILLING AND 
CAPPING CARBON NANOTUBES
As mentioned previously, carbon nanotubes are end-
capped and thus for drug loading there are essentially two 
approaches which include the filling of carbon nanotubes 
during synthesis or after synthesis. Adding the contents of 
the nanotubes in-situ tends to be a less efficient approach, 
producing a yield of around 10% whereas the post-synthesis 
process can be better controlled and yields of 50-100% are 
achievable (Monthioux, 2002). The appropriate method 
depends on the material that is to be inserted into the CNT. 
The criteria include melting temperature, reactiveness, 
surface tension and sensitivity of the material.
Post-synthesis production of CNTs implies that the 
ends must be opened, This can be accomplished by passing 
electric currents through the CNT, through attacking the 
CNT with acid which corrodes the angled parts of the tube 
the most (i.e. the ends), or by oxidization using carbon 
dioxide (Tsang et al., 1994; Ajayan et al., 1993).There 
are two ways to include foreign particles in CNTs. One 
category is decoration, which is the process of bonding 
a functional group to CNTs (Ebbesen et al., 1996). This 
is difficult as carbon is rather inert, so oxidization is 
used to produce a more reactive attachment surface. The 
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functional group is either bonded to the inside or outside 
of the walls. The most common mechanism for filling 
CNTs is capillarity. The limiting factor in capillarity is the 
diameter of the CNT and the surface tension of the material 
(the threshold material surface tension is approximately 
200mN/m). However, according to (Gao et al., 2003), 
hydrophobic and Van der Waals forces also play a role 
in aqueous solutions. For chemicals with higher surface 
tensions it is possible to lower this tension by creating a 
suitable composite, which can be chemically reduced to 
the original substance once the CNT has been filled. The 
CNTs are washed using a solution which has been chosen 
to offer only limited solubility to the impregnating fluid 
and thus can dissolve only deposits left outside the CNT 
(Qiang et al., 2008). After filling, the CNTs are capped by 
passing a current which fuses the ends closed (de Jonge et 
al., 2005). The loading of CNTs remains an area requiring 
further research and more frequently mathematical 
methods are used rather than laboratory experiments due 
to the comparatively lower cost (Hilder et al., 2009).
Drug loading
The location of the drug to be delivered by the CNT 
can be internal or external. Internalisation or encapsulation 
relies on Van der Waals forces for insertion into the CNT 
and is best used for drugs that are sensitive to external 
environments and easily broken down (Hillebrenner et 
al., 2006).
Drug targeting
In tradit ional cancer treatments involving 
chemotherapeutic agents, drug delivery is unavoidably 
indiscriminate. The toxic drug treatment is therefore 
applied to both tumour and regular cells which has the 
effect of, at best, causing numerous unpleasant side-effects 
in the patient and, at worst, leading to the death of the 
patient due to the toxicity of the drugs themselves. If it 
were possible to target the delivery of chemotherapeutic 
agents to only the tumour cells then this would both 
decrease the adverse side effects and also allow more 
effective, concentrated doses/agents that would be too 
toxic for traditional chemotherapy.
There are two basic techniques used for targeted 
nanoscale drug delivery. The first is passive (or size-
mediated) targeting, where this relies upon the unique size 
of nanoparticles and the growth behavior of tumours. As 
the tumour grows it requires greater and greater amounts 
of oxygen and nutrients, engaging new blood vessels by 
a process called angiogenesis. Unlike in regular blood 
vessels, the endothelial cells (which regulate the transfer 
of molecules across the vessel) in tumours can be spaced 
as far apart as 600 nm from each other. This defect allows 
increased permeability of nanoparticles into the interstitial 
space. In addition, there is poor lymphatic drainage in 
these tumorous areas.
These combined effects lead to a phenomenon 
known as enhanced permeability and retention (EPR) 
(Figure 2). By proper design of nanoparticles, this 
effect can be harnessed to locally increase density of 
nanoparticles (and their therapeutic agents) in the tumour, 
up to at least 10 times that of drugs not transported via 
nanoparticles (Misra et al., 2010). Another effect of 
angiogenesis and the desire to increase supply of nutrients 
to the tumour cell is the process of glycolysis used to 
increase energy level. This has the resulting effect of a 
locally decreased pH. This could potentially be utilised 
as an effective means of controlled drug release within 
the cancerous tumour, given a nanotube capped with a 
substance biodegradable by an acidic environment (Misra 
et al., 2010). The second technique is active targeting - this 
involves using antibody- or ligand-targeted binding as a 
means of selective delivery to cancer cells or tumours. 
This technique requires knowledge of the target receptor 
or antigen on the cancer cells, preferably with a number of 
properties that are unique to the cancer cells and that are 
FIGURE 2 - Active targeting and EPR effect (Wang et al., 2009).
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expressed with high enough density to distinguish them 
from surrounding healthy cells (Wang et al., 2009).
Research has shown that nanoscale drug delivery 
devices can be targeted specifically at cancer cells using 
the latter method, albeit mostly in laboratory tests. 
Applications for diagnosis and therapeutic treatment by 
other imaging agents and drug delivery vehicles such 
as repeatedly-branched, spherical dendrimers (typically 
by covalent bonding to the molecules periphery or outer 
functional groups (Morgan et al., 2006)) or robust silica-
coated micelles for delivery of hydrophobic anti-cancer 
agents (Huo et al., 2006) could also be employed using 
carbon nanotubes as a potential delivery vehicle. Central to 
a nanoparticle’s efficacy when it enters the body is its ability 
to bypass the immune system for at least as long as it takes 
to reach and react to the cancer cells. For example, polymer-
coated liposomes of the first generation were cleared by the 
mononuclear phagocytic system (MPS) within minutes. The 
second generation has a modified liposome surface that, 
unlike the unmodified phospholipid liposome surface, does 
not attract plasma proteins and hence the MPS. This allows 
the liposomes to remain circulating within the blood for 
much longer and are hence more likely to reach their target, 
either passively or actively (Papahadjopoulos et al., 1990). 
Similar techniques are required to ensure high circulation 
periods when nanotubes are used.
Thermal ablation is a unique property attached with 
nanotubes to cause an increase of 10 0C, the temperature 
rise required to induce a form of hyperthermia in the 
cells, ultimately causing their death (Burke et al., 2009). 
It is a universal means of destroying any type of cancer. 
Currently thermal ablation of tumour cells is done by 
radiofrequency-based heating of an ablation catheter 
which is inserted into the tumour with the assistance 
of an ultrasound transducer for imaging, When the 
catheter is in place, radiofrequency energy is applied 
via the catheter into the tissue which is then absorbed as 
thermal energy, destroying the cells. The success of this 
technique depends heavily on the surgeon’s accuracy when 
inserting the catheter. By using targeted nanotubes and 
the aforementioned properties of these when exposed to 
near infra-red (NIR) light, more accurate, reliable thermal 
ablation is achievable without requiring an incision (Liu 
et al., 2009; Chakravarty et al., 2008).
Another phenomenon and potential use of NIR light 
in conjunction with CNTs is in the triggered release of the 
drug payload. It was found that six 10 second pulses at 
1.4W/cm2 intensity released a DNA cargo into the occupied 
cell (Kam et al., 2005). The release of the payload was 
not accompanied by cellular destruction, enabling precise 
control of the therapeutic treatment. An additional benefit of 
the increased local temperature is the enhanced permeability 
of the tumour vasculature. This improves drug uptake into 
the tumour resulting in more effective chemotherapeutic 
treatment. It is conceivable that CNTs could be utilised 
as both a drug-delivery vehicle and as a means of thermal 
ablation, improving the efficacy of treatment yet with 
reduced intensity (Burke et al., 2009).
Passive and active targeting
Previous attempts at antibody-mediated drug 
delivery have been largely unsuccessful due to the loss 
of specificity of the antibodies on binding with drug 
molecules. It was found that using nanotubes to support 
antibodies did not change their properties and so did 
not inhibit their targeting abilities. Targeting methods 
such as active or passive targeting are a direct result of 
functionalisation. Passive targeting is a result of inertness 
and physical size of the macromolecule, “hiding” it 
from the immune system. CNTs must be nanosized to 
prevent cellular opsonisation (the susceptibility of the 
macromolecule to ingestion by phagocytes resulting in 
its destruction) by the innate immune system but also 
functionalised with molecules/polymer chains such as 
PEG which do not promote an adaptive immune response. 
The CNT must also be of sufficient size to utilise the 
EPR effects and so a trade-off is required. PEG is useful 
in determining the degree of optimal functionalisation 
as it is an easily controllable variable. This passive 
targeting can cause problems; microspheres can lead to 
chemoembolism-type problems in the lymphatic nodes. 
For such cases, functionalisation with nanomagnetic 
particles (e.g. iron oxide) and placing of a magnet at the 
desired location for extended periods of time allows for 
drug release over an extended period. Active targeting 
requires functionalisation with tumour-specific binding 
sites to selectively bind to tumour cells. Many cells 
of various cancers are known to overexpress certain 
receptors, such as brain tumours showing typically 100 
k to 900 k LDL (low density lipoprotein) receptors. 
Functionalising CNTs with LDL not only increases uptake 
dramatically in the cancer cells, but reduces uptake in other 
cells that have far fewer LDL receptors.
Crossing the blood-brain barrier
Many drugs also suffer from an inability to reach 
tumours. The blood-brain barrier prevents drugs from 
destroying brain tumours. By attaching chemotherapy 
drugs to a CNT, this problem is overcome, as CNTs can 
cross the blood-brain barrier (Beg et al., 2011).
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Drug delivery targeted to lymphatic system
Many cancers metastasize through the lymphatic 
canal. Drug delivery systems targeted to the lymphatic 
system can block the metastasis of cancers effectively. 
Using radical polymerization, polyacrylic acid (PAA) can 
be appended onto CNTs, making them highly hydrophilic. 
Through coprecipitation, Fe3O4-based magnetic 
nanoparticles can be adsorbed on the PAA-CNT surface.
Through the interaction with COOH groups of 
grafted PAA, the nanoparticles can be stabilized from 
clustering. By stirring the solution containing PAA-CNT, 
Fe3O4-based magnetic nanoparticles, and gemcitabine for 
24 h, gemcitabine was loaded into the nanosystem with a 
loading efficiency of 62%. It was found that CNTs were 
seen only in the local lymphatic nodes and were absent in 
the major organs, such as liver, kidney, heart, spleen, and 
lungs, after 3 h of subcutaneous injection. Without the help 
of such a nanostructures (Yang et al., 2010), gemcitabine 
cannot preferentially distribute in the lymphatic system.
FUNCTIONALISATION
Raw carbon nanotubes have highly hydrophobic 
surfaces and are not soluble in aqueous solutions whereas 
pristine CNTs are not soluble in any solution. A solution 
to this problem is Functionalisation. Functionalisation of 
CNTs is a process of chemical synthesis where desired 
functional groups can be introduced onto the walls of 
CNTs for various applications producing functionalised 
carbon nanotubes (f-CNT). The aim of this process in 
cancer treatment is the enhancement of biocompatibility 
within the body, enhancement of encapsulation tendency 
and solubility, multimodal drug delivery, and imaging 
with the specific properties imparted related to the desired 
function. Modifications to CNTs can be divided into two 
categories; covalent and noncovalently bonded.
Covalent bonding
Covalent chemical bonding of polymer chains to 
CNTs results in strong chemical bonds between nanotubes 
and the attached molecule. Various covalent reactions 
have been developed to graft molecules based on their 
varying properties and can be further classified as Grafting 
to or Grafting from reactions, which involve the addition 
of preformed polymer chains or the polymerisation of 
monomers from surface derived initiators on CNTs, 
respectively. Both to and from methods involve reaction 
to the surface of CNT by functionalisation reactions. 
Molecules or polymer chains reacting with the surface 
of pristine, pre-functionalised or oxidised CNTs are the 
three main methods used to attach molecules covalently. 
Oxidation of CNTs, representing one of the most common 
modifications, uses oxidising agents such as concentrated 
nitric acid to form carboxyl groups at the most reactive 
sites; i.e. the ends, which are more reactive, and on any 
defects on the walls, such as 5-membered rings (Bianco 
et al., 2005; Singh et al., 2005; Prato et al., 2008). The 
curvature of the CNT places a strain on the sp2 hybridised 
carbon atoms, reducing the energy barrier required to 
convert the sp2 hybridized bonds to sp3 compared with flat 
graphene. This results in pristine CNT being susceptible 
to various addition reactions such as the Bingel reaction 
(Bianco et al., 2005; Singh et al., 2005; Prato et al., 2008). 
Covalent bonding gives a robust attachment which is 
generally stable in a bioenvironment. However, intrinsic 
physical properties of CNTs such as photoluminescence 
and Raman scattering are drastically reduced due to the 
disruption to the CNT structure associated with covalent 
bonding. Due to this, covalent bonding cannot be used to 
functionalise CNTs used for photothermal ablation or for 
imaging purposes. A number of covalent functionalisation 
reactions have been used to modify carbon nanotubes to 
suit various applications (Spitalsky et al., 2010).
Non-covalent bonding
Non-covalent bonding of molecules to CNTs is 
generally the more widely used method of drug delivery 
according to the literature. An ideal non-covalently 
functionalised CNT should have specific properties; 
the more closely matched, the greater the usefulness 
in biological roles. This can be carried out by creating 
micelle-type structures where amphiphilic molecules 
are coated to the CNT. Another common form of 
functionalisation is π-π bonding achieved by stacking 
pyrene molecules onto the surface of the CNT. This type 
of bonding can also be applied to single strands of DNA by 
virtue of the aromatic DNA base units. This was shown to 
be unstable as it is cleaved by nucleases and consequently 
the biological applications are so far limited. Non-covalent 
bonding does not disrupt the π – network where, except 
for a shortening of length, the physical properties of the 
CNTs are essentially preserved, showing great promise 
for imaging and photothermal ablation (Liu et al., 2009).
ATTACHMENT OF DRUG TO CNT AND ITS 
RELEASE
External attachment of drugs is usually achieved by 
attaching molecules by amide, ester or disulphide bonds. 
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This is in order to employ a bond that is biologically 
cleaved either near the cell or more usefully, within the 
cell, releasing the payload. In a recent study, it was found 
that the lack of enhanced efficacy between the delivery of 
methotrexate, an anti-cancer drug, and the nonconjugated 
drug was from the amide bond, attaching the drug to 
the f-CNT. The bond was found to be too stable and not 
biologically cleaved. Improved delivery can result from 
a bond that is biologically stable, so as not to breakdown 
before it has reached the required location, but can be 
enzymatically cleaved within the cell (Prato et al., 2008). 
The use of NIR to release CNT-encapsulated drugs is 
another promising release mechanism, as living organisms 
are generally transparent to NIR. This is particularly 
applicable to polar drugs which do not readily cross the 
lipid bilayer. The NIR heats the CNT and can be used to 
accelerate the diffusion of the molecule inside the tube 
to the cell. Extremely low diffusion coefficients trap 
molecules of high polarity. When heated, the diffusion 
coefficient increases up to 7-fold, facilitating the release 
of polar drugs (Chaban et al., 2010).
Kinetics of CNTs
As drug carriers, the administration, absorption, 
and transportation of CNTs must be considered for 
obtaining the desired treatment effects. The studied 
routes of CNT administration include oral and injections 
FIGURE 3 - Modification of SWCNTs. (1 Dhar et al., 2008, 2 
Jia et al., 2007, 3 Georgakilas et al., 2005, 4 Chen et al., 2010, 
5 Liu et al., 2008, 6 Meng et al., 2008, 7 Zheng et al., 2003, 8 
Hong et al., 2010).
such as subcutaneous injection, abdominal injection, 
and intravenous injection. There are different ways of 
absorption and transportation when CNTs are administered 
by different routes. The absorbed CNTs are transported 
from the administration sites to the effect-relevant sites 
by blood or lymphatic circulation. After administration, 
absorption is the first key step for drug carriers to complete 
their drug-delivering mission. Studies have suggested 
that CNTs themselves are capable of being absorbed. It 
has also been established that physically shortened CNTs 
that are orally administered can be absorbed through the 
columnar cells of intestinal mucous membrane, where 
this was confirmed by transmission electron microscopy 
(Liu et al., 2011).
Distribution indicates the sites or places the absorbed 
CNTs can arrive and exist, of great importance in clinical 
pharmacology and toxicology of CNTs as drug carriers. 
There have been experiments to investigate in vivo and 
ex vivo biodistributions, as well as tumor targeting ability 
of radiolabeled SWCNTs (diameter, approximately 1 to 5 
nm; length, approximately 100 to 300 nm) noncovalently 
functionalized with phospholipids(PL)- PEG in mice using 
positron emission tomography and Raman spectroscopy, 
respectively. It was interesting to note that the PEG chain 
lengths determine the biodistribution and circulation of 
CNTs.
The nonbiodegradability in the body and non-
eliminability from the body raise questions on the 
possibility of their successful use in clinical practice, 
factors which have always been a concern. Functionalized 
SWCNTs seem to be metabolizable in the animal body. 
For example, SWCNTs with carboxylated surfaces have 
demonstrated their unique ability to undergo 90-day 
degradation in a phagolysosomal simulant, resulting in 
shortening of length and accumulation of ultrafine solid 
carbonaceous debris. Unmodified, ozonolyzed, aryl-
sulfonated SWCNTs exhibit no degradation under similar 
conditions. The observed metabolism phenomenon may be 
accredited to the unique chemistry of acid carboxylation, 
which, in addition to introducing the reactive, modifiable 
COOH groups onto CNT surfaces, also induces collateral 
damage to the tubular graphenic backbone in the form of 
neighboring active sites that provide points of attack for 
further oxidative degradation (Raffa et al., 2010).
BIOCOMPATIBILITY OF CNTS AND ITS 
ENHANCEMENT
An ideal (non-covalent) functionalisation coating 
should have the following properties (Liu et al., 2009):
·	 Coating should be nontoxic and biocompatible
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·	 Coating should be sufficiently stable to resist de-
tachment from nanotube surface under biological 
conditions
·	 Amphiphilic coating molecules should have a low 
critical micelle concentration so CNT is stable once 
removed from solution 
·	 Coating should have functional groups which are 
available for bioconjugation with antibodies or 
other molecules to create various CNT conjugates 
for various applications.
Producing biocompatible CNT requires low 
levels of toxicity and to ease-of-processing by the body. 
Addition of polyethylene glycol (PEG) by attachment 
via phospholipids allows for this, as both constituents 
are easily removed from the body over time. The toxicity 
is greatly reduced by functionalisation (Bianco et al., 
2005). A problematic feature of many current drugs 
is the circulation time in vivo which in vitro testing 
cannot determine. Low circulation times greatly reduce 
effectiveness as the drug is removed from the body too 
quickly, whereas long circulation times have a detrimental 
effect on healthy tissue increasing the side effects. f-CNT 
can tailor the blood circulation half-life so as to maximize 
absorbance by tumours, but minimise the accumulation in 
skin dermis, for example. The extent of functionalisation 
with polymers such as PEG and the length of these chains 
play an in important role in biodistribution. Increasing 
the extent (i.e. the density) of PEGylation (PEGylation 
is the process of covalent attachment of polyethylene 
glycol polymer chains) and the lengths of polymer 
chains, increased the circulation time in in vivo studies 
on mice. Densities of 10% PEGylation and chain lengths 
of 5k monomer units were found to have ideal half-life 
circulation times of 12-13 hours with high uptakes in 
tumours but low uptakes in other cells such as skin dermis. 
This is a good example of how functionalisation can be 
finely tuned to optimise the in vivo behaviour of f-CNT as 
well as applications in general (Raffa et al., 2010).
Cell uptake is partially dependent on the length of 
CNTs and is another criteria to be taken into account when 
attempting to find design criteria for CNT carrier systems. 
CNTs having lengths within the submicron range were 
found to readily accumulate in cells (Shvedova et al., 
2010); further suggesting surface chemistry has a minor 
role in the uptake. Most studies carried out use varying 
lengths of CNT, but with more specific manufacturing 
techniques available, future work should look in more 
detail at the optimal length for varying applications.
Toxicity of carbon nanotubes
As has been mentioned in this paper, carbon nanotubes 
are a high-profile, nano-scale technology that is being 
considered in many technological fields. Increasingly 
however, concerns have been raised over potential toxicity 
issues with carbon nanotubes (Firme et al., 2010; Pacurari 
et al., 2008) and there is presently a lack of data and 
understanding about their impact on biological systems. 
Given the probable wide-spread use of CNTs in the future, 
it is imperative to understand their impacts on biological 
systems before they can be used in mainstream drug 
delivery. The most attractive properties of nano-materials 
for biomedical applications i.e. their small size, large surface 
area, high reactivity, and high aspect ratio, are also the main 
factors of potential cytotoxicity. It is thought that, although 
there may be several mechanisms of causing cell damage, 
the main way would be due to DNA damage (Ji et al., 
2010). The study suggests that SWCNTs can induce adverse 
cellular responses through activation of molecular signaling 
associated with oxidative stresses (cancer inducing).
Several groups have already observed that CNTs can 
exhibit behaviour similar to that of asbestos fibres when 
conducting experiments on mice (Thurnherr et al., 2011). 
FIGURE 4 – Structure of Chrysotile Asbestos (left) and MWCNT (right).
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This concern becomes understandable when the structure 
of both compounds is compared. Structures of chrysotile 
asbestos (left) and MWCNT (right) are shown above. The 
main issue with asbestos (and the concern with CNTs) is 
that due to their nano-scale and light weight, they easily 
become airborne and are carried into the lungs. Asbestos 
is known to have caused scarring of the lungs (pulmonary 
fibrosis). This leads to a host of health problems and 
diseases due to the reduced surface area within the lung to 
transfer oxygen into the blood stream. CNTs resemblance 
to asbestos fibres, in terms of aspect ratio, bio-persistence 
and reactivity contribute to this concern. Whilst there 
is good reason to be concerned about the potential 
similarities to asbestos fibres, there is evidence to suggest 
that industrially produced MWCNTs in high doses do not 
result in cell death in lung epithelial (tissue) in the way 
that asbestos fibres do. Additionally, long term exposure 
to pristine MWCNTs at low concentrations did not cause 
any major adverse effects (Lindberg et al., 2009).
Factors found to affect CNT toxicity
A list of factors that have been found to have an 
influence on the degree of toxicity of CNTs (Thurnherr et 
al., 2011) follows below:
·	 Concentration / dose of CNTs.
·	 SWCNTs or MWCNTs
·	 Length of the tubes
·	 Catalyst residues left over during synthesis or func-
tionalization
·	 Degree of aggregation
·	 Oxidisation
·	 Functionalisation.
Whilst many studies show conflicting results on 
some of these properties, two seem to yield the most 
concurrent results; concentration and functionalisation. 
Various studies have been conducted with regard to the 
effect of dose concentration on cell viability. The two 
parameters used to monitor this test are concentration 
of dose and incubation time. It has been shown using 
rat erythrocytes (red blood cells) that at MWCNT 
concentrations of 25 µg/mL no adverse effects to the cells 
were observed. At concentrations of 50 µg/mL however, 
erythrocyte haemolysis (breaking of the cell membrane) 
was increased. One likely explanation is that at these 
higher concentrations the MWCNTs agglomerate, which 
appears to accelerate the haemolysis process (Bottini et 
al., 2006).
Several papers agree that high dose concentrations 
and prolonged incubation times both increase the induced 
toxicity and thus decrease cell viability. Research has 
shown cell viability decreases significantly in human 
bronchial epithelial cells. (Kalaugher et al., 2005) The 
trend shows how DNA damage increases considerably 
with dose concentration of SWCNTs (non-functionalised 
SWCNT). The concentration and incubation time of a 
dose is an area of nanotechnology in cancer treatment 
which requires much further study, as it will be important 
to optimise these for the treatment and eradication of 
cancerous growths as well as to minimise the body’s 
exposure to the drug (should it prove to have a degree 
of toxicity). The focus of a large body of research has 
been the degree to which functionalisation affects 
CNT toxicity. This is also likely to be one of the 
areas of research that receives most attention because 
active and passive targeting is directly related to the 
TABLE I - List of anticancer drugs delivered using CNTs
S.N. Name of Drug Modification / Functionalization SWCNT / MWCNT Advantage
1 Doxorubicin (Heister et al., 2006; 
Xiaoke et al.,2009)
PEG conjugation SWCNT Reduced toxicity
2 Mitoxantrone (Heister et al., 2006) PEG conjugation SWCNT Reduced toxicity
3 Paclitaxel (Tian et al., 2011) PEG conjugation SWCNT Increased circulation period
4 Cisplatin (Liu et al., 2007) Non functionalised SWCNT Decreased toxicity
5 Carboplatin (Hampel et al., 2008) SWCNT
6 Doxorubicin (Li et al., 2011) Conjugated with folate MWCNT Active targeting
7 Paclitaxel (Tian et al., 2011) Folate conjugate MWCNT Increased circulation period
8 Methotrexate (Modi et al., 2011) PEGlyated MWCNT Controlled toxicity
9 Quercitin (Dolatabadi, et al., 2011) PEGylated SWCNT Reduced side effect
10 Folic Acid (Reddy et al., 2006) – MWCNT Active targeting, longer 
circulation period
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type and degree of functionalisation of the CNT. It 
has been demonstrated that increasing the degree of 
functionalisation of a SWCNT can dramatically decrease 
its cytotoxicity. (Azizian et al., 2010) The executive 
director for the Centre for Biological and Environmental 
Nanotechnology (CBEN) has stated regarding this 
study “...it’s the same answer: change the surfaces. This 
is an important demonstration that there are general 
trends in biological responses to nano-particles”. Long 
side-chain functional groups on SWCNTs can lower 
toxicity and have been shown to increase the CNTs 
biocompatibility with cells. This property of CNTs for 
cancer treatment appears to be particularly promising, as 
the functionalisation of CNTs is essential for passive and 
active cancer treatment (Yang et al., 2010).
CONCLUSION
In the field of CNT technology for cancer treatment, 
the issues surrounding CNT toxicity remain inconclusive, as 
there are numerous conflicting studies demonstrating both 
toxic and non-toxic behavior, in spite of a number of drugs 
which have been delivered using carbon nanotubes. [Table 
1] This is in part; it seems, due to the nature of the research 
being conducted. That is, there is no real benchmark for 
comparing results. Due to the range of parameters listed 
earlier which have been shown to affect CNTs toxicity, 
this is an area which will require the continual attention 
of toxicologists in the future. Using just one example, 
some evidence (Thurnherr et al., 2011) points to Fe (iron) 
impurities on CNTs at high concentrations increasing 
the observed cytotoxic response, while other research 
(Kolosnjaj-Tabi et al., 2010) claims the opposite. Clearly, 
much further study is required in this area before CNT 
technology can be applied to cancer treatment. That said, it 
is an extremely promising application of nano-technology 
and is definitely worth further research, as the current 
methods for cancer treatment are indiscriminately harmful 
and only partially effective.
REFERENCES
ABARRATEGI, A.; GUTIERREZ, M.C.; MORENO-
VICENTE, C.; HORTIGUELA, M.J.; RAMOS, V.; 
LOPEZ-LACOMBA, J.L. Multiwall carbon nanotube 
scaffolds for tissue engineering purposes. Biomaterials, 
v.29, n.1, p.94-102, 2008.
AJAYAN, P.M.; EBBESEN, T.W.; ICHIHASHI, T.; IIJIMA, 
S.; TANIGAKI, K.; HIURA, H. Opening carbon nanotubes 
with oxygen and implications for filling. Nature, v.362, 
n.6420, p.522-525, 1993.
ALDERTON, P.M.; GROSS, J.; GREEN, M.D. Comparative 
study of doxorubicin, mitoxantrone, and epirubicin in 
combination with ICRF-187 (ADR-529) in a chronic 
cardiotoxicity animal model. Cancer Res., v.52, n.1, p.194-
201, 1992.
ALI-BOUCETTA, H.; AL-JAMAL, K.T.; MCCARTHY, D.; 
PRATO, M.; BIANCO, A.; KOSTARELOS, K. Multiwalled 
carbon nanotube-doxorubicin supramolecular complexes 
for cancer therapeutics. Chem. Commun, v.28, n.4, p.459-
461, 2008.
ALPATOVA, A.L.; SHAN, W.; BABICA, W. Single-walled 
carbon nanotubes dispersed in aqueous media via non-
covalent functionalization: effect of dispersant on the 
stability, cytotoxicity, and epigenetic toxicity of nanotube 
suspensions. Water Res., v.44, n.2, p.505-520, 2010.
AZIZIAN, J.; TAHERMANSOURI, H.; BIAZAR, E.; 
HEIDARI, S.; KHOEI, D.C. Functionalization of 
carboxylated multiwall nanotubes with imidazole 
derivatives and their toxicity investigations. Int. J. 
Nanomedicine, v.5, p.907-914, 2010.
BEG, S.; RIZWAN, M.; SHEIKH, A.M.; HASNAIN, M.S.; 
ANWER, K.; KOHLI, K. Advancement in carbon 
nanotubes: basics, biomedical applications and toxicity, J. 
Pharm. Pharmacol., v.63,n.2, p.141-163, 2011.
BIANCO, A.; KOSTARELOS, K.; PRATO, M. Applications of 
carbon nanotubes in drug delivery. Curr. Opin.Chem. Biol., 
v.9,n.6, p.674-679, 2005.
BOTTINI, M.; CERIGNOLI, F.; DAWSON, M.I.; MAGRINI, 
A.; ROSATO, N.; MUSTELIN, T. Full-length single-walled 
carbon nanotubes decorated with streptavidin-conjugated 
quantum dots as multivalent intracellular fluorescent 
nanoprobes. Biomacromolecules, v.7, n.8, p.2259-2263, 
2006.
BURKE, A.; DING, X.; SINGH, R. Long-term survival 
following a single treatment of kidney tumors with 
multiwalled carbon nanotubes and near-infrared radiation. 
Proc. Natl. Acad. Sci., v.106, n.31, p.12897-12902, 2009.
CAI SHAO‐YU; KONG JI‐LIE. Advance in research on carbon 
canotubes as diagnostic and therapeutic agents for tumour. 
Chinese J. Anal. Chem., v.37, n.8, p.1240-1246, 2009.
Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review 639
CAI, D.; DOUGHTY, C.A.; POTOCKY, T.B.; DUFORT, 
F.J.; HUANG, Z.; BLAIR, D. Carbon nanotube-mediated 
delivery of nucleic acids does not result in non-specific 
activation of B lymphocytes. Nanotechnology, v.18, n.365, 
p.101-110, 2007.
CATO, M.H.; D’ANNIBALE, F.; MILLS, D.M.; CERIGNOLI, 
F.; DAWSON, M.I.; BERGAMASCHI, E. Cell-type 
specific and cytoplasmic targeting of PEGylated carbon 
nanotubebased nanoassemblies. J. Nanosci. Nanotechnol., 
v.8, n.5, p.2259-2269, 2008.
CHABAN, V.V.; SAVCHENKO, T.I.; KOVALENKO, S.M.; 
PREZHDO, O.V. Heat-driven release of a drug molecule 
from carbon nanotubes: a molecular dynamics study. J. 
Phys. Chem., v.114, n.42, p.13481-13486, 2010.
CHAKRAVARTY, P.; MARCHES, R.; ZIMMERMAN, 
N.; SWAFFORD, A.; BAJAJ, P.; MUSSELMAN, I.; 
PANTANO, P.; DRAPER, R.; VITETTA, E. Thermal 
ablation of tumor cells with antibody-functionalized single-
walled carbon nanotubes. Proc. Natl. Acad. Sci., v.105, n.25, 
p.8697-8702, 2008.
CHEN, D.; WU, X.; WANG, J.; HAN, B.; ZHU, P.; PENG, C.H. 
Morphological observation of interaction between PAMAM 
dendrimer modified single walled carbon nanotubes and 
pancreatic cancer cells. Nano Biomed. Eng., v.2, n.4, p.60-
65, 2010.
CHEN, J.Y.; CHEN, S.Y.; ZHAO, X.R.; KUZNETSOVA, 
L.V.; WONG, S.S.; OJIMA, I. Functionalized single-
walled carbon nanotubes as rationally designed vehicles 
for tumortargeted drug delivery. J. Am. Chem. Soc., v.130, 
n.49, p.16778-16785, 2008.
CHIN,  S .F. ;  BAUGHMAN, R.H. ;  DALTON,  A.B. ; 
DIECKMANN, G.R.; DRAPER, R.K.; MIKORYAK, C. 
Amphiphilic helical peptide enhances the uptake of single-
walled carbon nanotubes by living cells. Exp. Biol. Med., 
v.232, n.9, p.1236-1244, 2007.
CHITHRANI, B.D.; GHAZANI, A.A.; CHAN, W.C.W. 
Determining the size and shape dependence of gold 
nanoparticle uptake into mammalian cells. Nano Lett., v.6, 
n.4, p.662-668, 2006.
CHONN, A.; CULLIS, P.R. Recent advances in lipo-somal 
drug-delivery systems. Curr. Opin. Biotechnol., v.6, n.6, 
p.698-708, 1995.
DEJONGE, N.; DOYTCHEVA, M.; ALLIOUX, M.; KAISER, 
M.; MENTINK, S.; TEO, K.; LACERDA, R.; MILNE, W. 
Cap closing of thin carbon nanotubes. Adv. Mater., v.17, 
n.4, p.451-455, 2005.
DHAR, S.; LIU, Z.; THOMALE, J.; DAI, H.; LIPPARD, S.J. 
Targeted single-wall carbon nanotube mediated Pt (IV) 
prodrug delivery using folate as a homing device. J. Am. 
Chem. Soc., v.130, n.34, p.11467-11476, 2008.
DOLATABADI, J.E.N.; JAMALI, A.A.; HASANZADEH, 
M. Quercetin delivery into cancer cells with single walled 
carbon nanotubes. Int. J. Biosci. Biochem. Bioinforma., v.1, 
n.1, p.21-25, 2011.
DOLATABADI, J.E.N.; MASHINCHIAN, O.; AYOUBI, B.; 
JAMALI, A.A.; MOBED A.; LOSIC, D.; OMIDI, Y.; 
GUARDIA, M. Optical and electrochemical DNA nano-
biosensors. Trend Anal. Chem., v.30, n.3, p.459-472, 2011.
EBBESEN, T.W. Wetting, filling and decorating carbon 
nanotubes. J. Phys. Chem. Solids, v.57 n.6-8, p.951-955, 
1996.
ENDO, M.; STRANO, M.S.; AJAYAN, P.M. Potential 
applications of carbon nanotubes. In: JORIO, A.; 
DRESSELHAUS, G.; DRESSELHAUS, M.S. (Ed.). Topics 
in applied physics. Berlin: Springer; Heidelberg: Verlag, 
2008. v.21, p.13-61.
FANG, J.; NAKAMURA, H.; MAEDA, H. The EPR effect: 
unique features of tumor blood vessels for drug delivery, 
factors involved, and limitations and augmentation of the 
effect. Adv. Drug Delivery Rev., v.63, n.3, p.136-151, 2011.
FIRME, C.P.; BANDARU, P.R. Toxicity issues in the application 
of carbon nanotubes to biological systems. Nanomedicine, 
v.6, n.2, p.245-256, 2010.
GAO, Y.K.; DX, C.; CS, O. Spontaneous insertion of dna 
oligonucleotides into carbon nanotubes. Nano Letters, v.3, 
n.4, p.471-473, 2003.
GEORGAKILAS, V.; TZITZIOS, V.; GOURNIS, D.; 
PETRIDIS, D. Attachment of magnetic nanoparticles on 
carbon nanotubes and their soluble derivatives. Chem. 
Mater., v.17, n.7, p.1613-1617, 2005.
S. K. S. Kushwaha, S. Ghoshal, A. K. Rai, S. Singh640
HAMPEL, S.; KUNZE, D.; HAASE, D. Carbon nanotubes 
filled with a chemotherapeutic agent: a nanocarrier mediates 
inhibition of tumor cell growth. Nanomedicine, v.3, n.2, 
p.175-182, 2008.
HASEGAWA, T.; FUJISAWA, T.; NUMATA, M.; UMEDA, 
M.; MATSUMOTO, T.; KIMURA, T. Single-walled 
carbon nanotubes acquire a specific lectin-affinity 
through supramolecular wrapping with lactose-appended 
schizophyllan. Chem. Commun., v.1, n.19, p.2150-2151, 
2004.
HEISTER, E.; NEVES, V.; TÎLMACIU, C.; LIPERT, K.; 
SANZ BELTRÁN, V.; COLEY, H. Triple functionalisation 
of single-walled carbon nanotubes with doxorubicin, a 
monoclonal antibody, and a fluorescent marker for targeted 
cancer therapy. Carbon, v.47, n.9, p.2152-2160, 2009.
HEISTER, E.; NEVES, V. Drug loading, dispersion stability, 
and therapeutic efficacy in targeted drug delivery with 
carbon nanotubes. Carbon, v.128, n.2, p.10568-10571, 
2006.
HILLEBRENNER, H.; BUYUKSERIN, F.; KANG, M.; MOTA, 
M.O.; STEWART, J.D.; MARTIN, C.R. Corking nano test 
tubes by chemical self-assembly. J. Am. Chem. Soc., v.128, 
n.13, p.4236-4237, 2006.
HONG, S.Y.; TOBIAS, G.; AL-JAMAL, K.T.; BALLESTEROS, 
B.;  ALI-BOUCETTA, H.;  LOZANO-PEREZ, S.; 
NELLIST, P.D.; SIM, R.B.; FINUCANE, C.; MATHER, 
S.J.; GREEN, M.L.; KOSTARELOS, K.; DAVIS, B.G. 
Filled and glycosylated carbon nanotubes for in vivo 
radioemitter localization and imaging. Nat. Mat., v.9, n.6, 
p.485-490, 2010.
HUO, Q.; LIU, J.; WANG, L.-Q.; JIANG, Y.; LAMBERT, 
T.N.; FANG, E. A new class of silica cross-linked micellar 
coreshell nanoparticles. J. Am. Chem. Soc., v.128, n.19, 
p.6447-6453, 2006.
IANCU, C.; MOCAN, L. Advances in cancer therapy through 
the use of carbon nanotubemediated targeted hyperthermia. 
Int. J. Nanomedicine, v.6, p.1675-1684, 2011.
IIJIMA, S. Helical microtubules of graphitic carbon. Nature, 
v.354, n.6348, p.56–58, 1991.
DOLATABADI, J.E.N.; OMIDI, Y.; LOSIC, D. Carbon 
nanotubes as an advanced drug and gene delivery 
nanosystem. Curr. Nanosci., v.7, n.3, p.297-314, 2011.
JI, S.R.; LIU, C.; ZHANG, B.; YANG, F.; XU, J.; LONG, J.; 
JIN, C.; FU, D.L.; NI, Q.X.; YU, X.J. Carbon nanotubes 
in cancer diagnosis and therapy. Biochim. Biophys. Acta., 
v.1806, n.1, p.29-35, 2010.
JIA, N.; LIAN, Q.; SHEN, H.; WANG, C.; LI, X.; YANG, Z. 
Intracellular delivery of quantum dots tagged antisense 
oligodeoxynucleotides by functionalized multiwalled 
carbon nanotubes. Nano Lett., v.7, n.10, p.2976-2980, 2007.
KALAUGHER, L. Nanotube toxicity linked to functionalization. 
Technology Update (abbreviation), v.3, n.???, p.1-9, 2005.
KAM, N.W.S.; DAI, H.J. Carbon nanotubes as intracellular 
protein transporters: generality and biological functionality. 
J. Am. Chem. Soc., v.127, n.16, p.6021-6026, 2005.
KAM, N.W.S.; JESSOP, T.C.; WENDER, P.A.; DAI, H.J. 
Nanotube molecular transporters: internalization of carbon 
nanotube-protein conjugates into mammalian cells. J. Am. 
Chem. Soc., v.126, n.22, p.6850-6851, 2004.
KAM, N.W.S.; O’CONNELL, M.; WISDOM, J.A.; DAI, 
H.J. Carbon nanotubes as multifunctional biological 
transporters and near-infrared agents for selective cancer 
cell destruction. Proc. Natl. Acad. Sci., v.102, n.33, p.11600-
11605, 2005.
KANG, B.; YU, D.C.; CHANG, S.Q.; CHEN, D.; DAI, Y.D.; 
DING, Y.T. Intracellular uptake, trafficking and subcellular 
distribution of folate conjugated single walled carbon 
nanotubes within living cells. Nanotechnology, v.19, n.37, 
p.375103-375110, 2008.
KIM, S.N.; RUSLING, J.F.; PAPADIMITRAKOPOULOS, 
F. Carbon nanotubes for electronic and electrochemical 
detection of biomolecules. Adv. Mater., v.19, n.20, p.3214-
3228, 2007.
KOLOSNJAJ-TABI, J.; HARTMAN, K.B.; BOUDJEMAA, S.; 
ANANTA, J.S.; MORGANT, G.; SZWARC, H.; WILSON, 
L.J.; MOUSSA, F. In vivo behavior of large doses of 
ultrashort and full-length single-walled carbon nanotubes 
after oral and intraperitoneal administration to Swiss mice. 
ACS Nano, v.4, n.3, p.1481-1492, 2010.
KOSTARELOS, K.; LACERDA, L.; PASTORIN, G.; WU, 
W.; WIECKOWSKI, S.; LUANGSIVILAY, J. Cellular 
uptake of functionalized carbon nanotubes is independent 
of functional group and cell type. Nat. Nanotechnol., v.2, 
n.2, p.108-113, 2007.
Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review 641
LI, R.; WU, R.; ZHAO, L. Folate and iron difunctionalized 
multiwall carbon nanotubes as dual-targeted drug nano- 
carrier to cancer cells. Carbon, v.49, n.5, p.1797-1805, 
2011.
LI, R.B.; WU, R.; ZHAO, L.; WU, M.H.; YANG, L.; ZOU, H.F. 
P-glycoprotein antibody functionalized carbon nanotube 
overcomes the multidrug resistance of human leukemia 
cells. ACS Nano, v.4, n.3, p.1399-1408, 2010.
LINDBERG, H.K.; FALCK, G.C.-M.; SUHONEN, S.; 
VIPPOLA, M.;  VANHALA, E. ;  CATAL´AN, J . ; 
SAVOLAINEN, K.; NORPPA, H. Genotoxicity of 
nanomaterials: DNA damage and micronuclei induced 
by carbon nanotubes and graphite nanofibres in human 
bronchial epithelial cells in vitro. Toxicol. Lett., v.186, n.3, 
p.166-173, 2009.
LIU, S.Y.-W.; LEE, K.-F.; LAI, P.B.-S. Needle track seeding: a 
real hazard after percutaneous radiofrequency ablation for 
colorectal liver metastasis. World J. Gastroenterol., v.15, 
n.13, p.1653-1655, 2009.
LIU, X.; TAO, H.; YANG, K.; ZHANG, S.; LEE, S.-T.; LIU, Z. 
Optimization of surface chemistry on single-walled carbon 
nanotubes for in vivo photothermal ablation of tumors. 
Biomaterials, v.32, n.1, p.144-151, 2011.
LIU, Z.; CHEN, K.; DAVIS, C.; SHERLOCK, S.; CAO, Q.; 
CHEN, X.; DAI, H. Drug delivery with carbon nanotubes 
for in vivo cancer treatment. Cancer Res., v.16, n.???, 
p.6652-6660, 2008.
LIU, Z.; DAVIS, C.; CAI, W.B.; HE, L.; CHEN, X.Y.; DAI, 
H.J. Circulationand long-term fate of functionalized, 
biocompatible single-walled carbon nanotubes in mice 
probed by Raman spectroscopy. Proc. Natl. Acad. Sci., 
v.105, n.5, p.1410-1415, 2008.
LIU, Z.; FAN, A.C.; RAKHRA, K.; SHERLOCK, S.; 
GOODWIN, A.; CHEN, X. Supramolecular stacking of 
doxorubicin on carbon nanotubes for in vivo cancer therapy. 
Angew Chem. Int. Ed. Engl., v.48, n.41, p.7668-7772, 2009.
LIU, Z.; SUN, X.M.; NAKAYAMA-RATCHFORD, N.; DAI, 
H.J. Supramolecular chemistry on watersoluble carbon 
nanotubes for drug loading and delivery. ACS Nano, v.1, 
n.1, p.50-56, 2007.
LIU, Z.; TABAKMAN, S.; WELSHER, K.; DAI, H. Carbon 
nanotubes in biology and medicine: in vitro and in vivo 
detection, imaging and drug delivery. Nano Res., v.2, n.2, 
p.85-120, 2009.
LIU, Z.; WINTERS, M.; HOLODNIY, M.; DAI, H.J. RNA 
delivery into human T cells and primary cells with carbon-
nanotube transporters. Angew Chem. Int. Ed. Engl., v.46, 
n.12, p.2023-2027, 2007.
LIU, Z.; CAI, L. H.E.; NAKAYAMA, N.; CHEN, K.; SUN, 
X.; CHEN, X.; DAI. H. In vivo Biodistribution and highly 
efficient tumour targeting of carbon nanotubes in mice. Nat. 
Nanotechnol., v.2, n.1, p.47-52, 2007.
LONG, D.W.; WU, G.Z.; ZHU, G.L. Noncovalently modified 
carbon nanotubes with carboxymethylated chitosan: a 
controllable donor-acceptor nanohybrid. Int. J. Mol. Sci., 
v.9, n.2, p.120-130, 2008.
LÜER, L.; HOSEINKHANI, S.; POLLI, D.; CROCHET, J.; 
HERTEL, J.; LANZANI, G. Size and mobility of excitonsin 
(6,5) carbon nanotubes. Nat. Phys., v.5, n.1, p.54-58., 2009.
MENG, J.; JIE, M.; DUAN, J.; KONG, H.; LI, L.; WANG, C.; 
XIE, S.; CHEN, S.; GU, N.; XU, H.; YANG, X-D. Carbon 
nanotubes conjugated to tumor lysate protein enhance the 
efficacy of an antitumor immunotherapy. Small, v.4, n.9, 
p.1364-1370, 2008.
MISRA,  R. ;  ACHARYA, S . ;  SAHOO, S .K.  Cancer 
nanotechnology: application of nanotechnology in cancer 
therapy. Drug Discov. Today, v.15, n.19-20, p.842-850, 
2010.
MODI, C.D.; PATEL, S.J.; DESAI, A.B.; MURTHY, R.S.R. 
Functionalization and evaluation of PEGylated carbon 
nanotubes as novel drug delivery for methotrexate. J. Appl. 
Pharm. Sci., v.1, n.5, p.103-108, 2011.
MONTHIOUX, M. Filling single-wall carbon nanotubes. 
Carbon, v.40, n.10, p.1809-1823, 2002.
MORGAN, M.T.; NAKANISHI, Y.; KROLL, D.J.; GRISET, 
A.P.; CARNAHAN, M.A.; WATHIER, M.; OBERLIES, 
N.H.; MANIKUMAR, G.; WANI, M.C.; GRINSTAFF, 
M.W. Dendrimer-encapsulated camptothecins: increased 
solubility, cellular uptake, and cellular retention affords 
enhanced anticancer activity in vitro. Cancer Res., v.66, 
n.24, p.11913-11921, 2006.
S. K. S. Kushwaha, S. Ghoshal, A. K. Rai, S. Singh642
MU, Q.X.; BROUGHTON, D.L.; YAN, B. Endosomal leakage 
and nuclear translocation of multiwalled carbon nanotubes: 
developing a model for cell uptake. Nano Lett., v.9, n.12, 
p.4370-4375, 2009.
MUGURUMA, H.; MATSUI, Y.; SHIBAYAMA, Y. Carbon 
nanotube-plasma polymer-based amperometric biosensors: 
enzyme-friendly platform for ultrasensitive glucose 
detection. Jpn. J. Appl. Phys., v. 46, n.9A, p.6078-6082, 
2007.
NANDAKUMAR, A. Consolidated report of the population 
based cancer registries. National cancer registry programme. 
Indian Council of Medical Research, v.4, n.2, p.23-24, 2010. 
(Material not found! Please, see it if it is correct).
NUMATA, M.; ASAI, M.; KANEKO, K.; HASEGAWA, T.; 
FUJITA, N.; KITADA, Y. Curdlan and schizophyllan (beta-
1,3-glucans) can entrap single-wall carbon nanotubes in 
their helical superstructure. Chem Lett., v.33, n.3, p.232-
233, 2004.
PACURARI, M.; YIN, X.J.; ZHAO, J.; DING, M.; LEONARD, 
S.S.; SCHWEGLER-BERRY, D.; DUCATMAN, B.S.; 
SBARRA, D.; HOOVER, M.D.; CASTRANOVA, V.; 
VALLYATHAN, V. Raw single-wall carbon nanotubes 
induce oxidative stress and activate MAPKs, AP-1, 
NF-kappaB, and Akt in normal and malignant human 
mesothelial cells. Environ. Health Perspect, v.116, n.9, 
p.1211-1217, 2008.
PAN, D.J.; TURNER, J.L.; WOOLEY, K.L. Shell cross-
linked nanoparticles designed to target angiogenic blood 
vessels via alpha(v)beta(3) receptor-ligand interactions. 
Macromolecules, v.37, n.???, p.7109-7115, 2004.
PANTAROTTO, D.; SINGH, R.; MCCARTHY, D.; ERHARDT, 
M.; BRIAND, J.P.; PRATO, M. Functionalized carbon 
nanotubes for plasmid DNA gene delivery. Angew Chem. 
Int. Ed. Engl., v.43, n.39, p.5242-5246, 2004.
PAPAHADJOPOULOS, D.G.A. Liposomes designed to avoid 
the reticuloendothelial system. Prog. Clin. Biol. Res., v.343, 
p.85-93, 1990.
PRATO, M; KOSTARELOS K.A.B. Functionalized carbon 
nanotubes in drug design and discovery. Acc. Chem. Res., 
v.41, n.1, p.60-68, 2008.
FU, Q.; WEINBERG, G.; SU, D-S. Selective filling of carbon 
nanotubes with metals by selective washing. New Carbon 
Mater., v.23, n.1, p.17-20, 2008. 
RAFFA, V.; CIOFANI, G.; VITTORIO, O.; RIGGIO, C.; 
CUSCHIERI, A. Physicochemical properties affecting 
cellular uptake of carbon nanotubes. Nanomedicine, v.5, 
n.1, p.89-97, 2010.
REDDY, S.T.; REHOR, A.; SCHMOEKEL, H.G.; HUBBELL, 
J.A.; SWARTZ, M.A. In vivo targeting of dendritic cells in 
lymph nodes with poly(propylene sulfide) nanoparticles. J. 
Control. Release, v.112, n.1, p.26-34, 2006.
SHAO, N.; LU, S.; WICKSTROM, E.; PANCHAPAKESAN, 
B. Integrated molecular targeting of IGF1R and HER2 
surface receptors and destruction of breast cancer cells using 
single wall carbon nanotubes. Nanotechnology, v.18, n.31, 
p.315101-315109, 2007.
SHVEDOVA, A.A.; KAGAN, V.E. The role of nanotoxicology 
in realizing the ’helping without harm’ paradigm of 
nanomedicine: lessons from studies of pulmonary effects 
of single-walled carbon nanotubes. J.Intern. Med., v.267, 
n.1, p.106-118, 2010.
SINGH, R.; PANTAROTTO, D. Binding and condensation of 
plasmid DNA onto functionalized carbon nanotubes: toward 
the construction of nanotube-based gene delivery vectors. J. 
Am. Chem. Soc., v.127, n.12, p.4388-4396, 2005.
SINGH, R.; PANTAROTTO, D.; LACERDA, L.; PASTORIN, 
G.; KLUMPP, C.; PRATO, M. Tissue biodistribution and 
blood clearance rates of intravenously administered carbon 
nanotube radiotracers. Proc. Natl. Acad. Sci., v.103, n.9, 
p.3357-3362, 2006.
SPITALSKY, Z.; TASIS, D.; PAPAGELIS, K.; GALIOTIS, 
C. Carbon nanotubepolymer composites: chemistry, 
processing, mechanical and electrical properties. Prog. 
Polym. Sci., v.35, n.3, p.357-401, 2010.
TASIS, D.; TAGMATARCHIS, N.; BIANCO, A.; PRATO, M. 
Chemistry of carbon nanotubes. Chem. Rev., v.106, n.3, 
p.1105-1136, 2006.
TAYLOR, A.; TURNBULL, B. The potential use of carbon 
Nanotubes for cancer treatment. Nature, v.321, n.2, p.1-
16, 2011.
Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review 643
THURNHERR, T.; BRANDENBERGER, C.; FISCHER, K.; 
DIENER, L.; MANSER, P.; MAEDER-ALTHAUS, X.; 
KAISER, J.P.; KRUG, H.F.; ROTHEN-RUTISHAUSER, 
B.; WICK, P.A. comparison of acute and long-term effects 
of industrial multiwalled carbonnanotubes on human lung 
and immune cells invitro. Toxicol. Lett., v.200, n.3, p.176-
186, 2011.
TSANG, S.C.; CHEN, Y.K.; HARRIS, P.J.F.; GREEN, M.L.H. 
A simple chemical method of opening and filling carbon 
nanotubes. Nature, v.372, n.6502, p.159-162, 1994.
WANG, H.F.; WANG, J.; DENG, X.Y.; SUN, H.F.; SHI, Z.J.; 
GU, Z.N. Biodistribution of carbon single-wall carbon 
nanotubes in mice. J. Nanosci. Nanotechnol., v.4, n.8, 
p.1019-1024, 2004.
WANG, X. Fabrication of ultralong and electrically uniform 
single-walled carbon nanotubes on clean substrates. Nano 
Lett., v.9, n.9, p.3137-3141, 2009.
WANG, X.; WANG, Y. Advances of cancer therapy by 
nanotechnology. Cancer Res. Treat., v.41, n.1, p.1-11, 2009.
WELSHER, K.; LIU, Z.; DARANCIANG, D.; DAI, H. 
Selective probing and imaging of cells with single walled 
carbon nanotubes as near-infrared fluorescent molecules. 
Nano Lett., v. 8, n.2, p.586-590, 2008.
WORLE-KNIRSCH, J.M.; PULSKAMP, K.; KRUG, H.F. 
Oops they did it again! Carbon nanotubes hoax scientists 
in viability assays. Nano Lett., v.6, n.6, p.1261-1268, 2006.
XIAOKE, Z.; LINGJIE, M. Targeted delivery and controlled 
release of doxorubicin to cancer cells using modified single 
wall carbon nanotubes. Biomaterials, v.30, n.30, p.6041-
6047, 2009.
YANG, D.; YANG, F.; HU, J.; LONG, J.; WANG, C.; FU, D.; 
NI, Q. Hydrophilic multiwalled carbon nanotubes decorated 
with magnetite nanoparticles as lymphatic targeted drug 
delivery vehicles. Chem. Commun., n.29, p.4447-4449, 
2009.
YANG, Z.; ZHANG, Y.; YANG, Y.; SUN, L.; HAN, D.; HONG, 
L.I.; WANG, C. Pharmacological and toxicological target 
organelles and safe use of single-walled carbon nanotubes as 
drug carriers in treating Alzheimer disease. Nanomedicine, 
v.6, n.3, p.427-441, 2010.
YUAN, W.Z.; SUN, J.Z.; DONG, Y.Q.; HAUSSLER, M., 
YANG, F.; XU, H.P. Wrapping carbon nanotubes in 
pyrene-containing poly(phenylacetylene) chains: solubility, 
stability, light emission, and surface photovoltaic properties. 
Macromolecules, v.39, n.23, p.8011-8020, 2006.
ZEINELDIN, R.; AL-HAIK, M.; HUDSON, L.G. Role of 
polyethyleneglycol integrity in specific receptor targeting 
of carbon nanotubes to cancer cells. Nano Lett., v.9, n.2, 
p.751-757, 2009.
ZHANG, X.K.; MENG, L.J.; LU, Q.G.; FEI, Z.F.; DYSON, P.J. 
Targeted delivery and controlled release of doxorubicin to 
cancer cells using modified single wall carbon nanotubes. 
Biomaterials, v.30, n.30, p.6041-6047, 2009.
ZHANG, X.K.; WANG, X.F.; LU, Q.H.; FU, C.L. Influence of 
carbon nanotube scaffolds on human cervical carcinoma 
HeLa cell viability and focal adhesion kinase expression. 
Carbon, v.46, n.3, p.453-460, 2008.
ZHENG, M.; JAGOTA, A.; SEMKE, E.D.; DINER, B.A.; 
MCLEAN, R.S.; LUSTIG, S.R.; RICHARDSON, R.E.; 
TASSI, N.G. DNA-assisted dispersion and separation of 
carbon nanotubes. Nat. Mater., v.2, n.5, p.338-342, 2003.
ZHONG TIAN; YINFENG SHI; MIN YIN; HEBEI SHEN; 
NENGQIN JIA. Functionalized multiwalled carbon 
nanotubes-anticancer drug carriers: synthesis, targeting 
ability and antitumor activity. Nano Biomed. Eng., v.3, n.3, 
p.157-162, 2011.
Received for publication on 27th August 2012
Accepted for publication on 23rd July 2013
